The last targeted thorium-227 conjugate reported was towards PSMA or more specifically, glutamate carboxypeptidase II (GPCII) regulated by folate hydrolase 1 (FOLH1) gene and specific of prostate cancer cells (including in mCRPC). Here, FOLH1 is linked to prostate cancer.